Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 vs Prevnar 13 in Older Adults Previously Vaccinated with PPSV23
NCT02573181Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Jan 2016
- Modality
- Split/Subunit Vaccines
01
Overview
Phase 2, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With an Adverse Event (AE) at Day 44, Percentage of Participants With a Solicited Injection-site Adverse Event (AE) at Day 5 and 4 more. Started Oct 2015; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02573181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573181.